Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

NCT ID: NCT06845163

Last Updated: 2025-06-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-08
• Study Completion Date: 2026-08-31

Brief Summary

The purpose of this clinical study is to explore the efficacy of dapagliflozin as an adjunct to intravitreal anti-vascular endothelial growth factor (anti-VEGF) for enhanced reduction of retinal thickness and vision improvement in patients with diabetic macular edema. The main question the study aims to answer is: Does dapagliflozin reduce the thickness of the macula when combined with the standard of care intravitreal anti-VEGF therapy more than the intravitreal anti-VEGF therapy alone?

Detailed Description

Some evidence in the literature suggests that sodium glucose co-transporter 2 (SGLT2) inhibitors may be beneficial in reducing diabetic macular edema. The objective of this clinical trial is to investigate the efficacy and safety of dapagliflozin when combined with intravitreal aflibercept injections in the management of patients with type II diabetes mellitus and center-involved diabetic macular edema (ci-DME). This randomized, double-blind, parallel group, active control design, clinical trial, is investigating the effect of oral dapagliflozin 10 mg given once daily in addition to intravitreal aflibercept versus intravitreal aflibercept alone on reducing macular central subfield thickness (CST) and improving visual acuity in diabetic patients with ci-DME.

Conditions

Diabetic Macular Edema; Center-involved Diabetic Macular Edema

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Treatment group

The treatment group will receive oral dapagliflozin 10 mg daily in addition to standard of care intravitreal aflibercept injections.

Group Type: EXPERIMENTAL

Dapagliflozin

Intervention Type: DRUG

Dapagliflozin 10 mg will be given orally once daily for three months.

Anti-VEGF drug

Intervention Type: DRUG

Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.

Control group

The control group will receive standard of care intravitreal aflibercept injections.

Group Type: ACTIVE_COMPARATOR

Anti-VEGF drug

Intervention Type: DRUG

Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.

Interventions

Dapagliflozin

Dapagliflozin 10 mg will be given orally once daily for three months.

Intervention Type: DRUG

Anti-VEGF drug

Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.

Intervention Type: DRUG

Other Intervention Names

Forxiga 10 mg; Aflibercept (Eylea)

Eligibility Criteria

Inclusion Criteria

• Type II diabetes mellitus patients, treated with premixed insulin and metformin, and diagnosed with center-involved diabetic macular edema (CiDME)
• Presence of retinal thickening involving the center of the fovea (CiDME) in the study eye on Optical Coherence Tomography (OCT) Heidelberg Spectralis; If both eyes are eligible, the eye with the greater central subfield thickness on OCT is selected as the study eye.
• Decreased visual acuity primarily attributable to DME
• Clear ocular media and pupillary dilation for adequate retinal imaging
• Ability to understand the study procedures and willingness to provide written informed consent

Exclusion Criteria

• Patients below 18 years old and patients above 85 years old
• Patients with type I diabetes mellitus (Insulin dependent diabetes mellitus IDDM)
• Pregnant women and lactating women diagnosed with diabetes or intending to become pregnant in the next 12 months
• Patients who had myocardial infarction within 3 months prior to screening
• Patients who had transient ischemic attack (TIA), ischemic or hemorrhagic stroke within 3 months prior to screening
• Patients with poorly controlled diabetes mellitus, defined as patients having glycosylated hemoglobin (HbA1c) level of ≥12% at screening or patients who were hospitalized for diabetic ketoacidosis or hyperosmolar coma within 4 months prior to screening
• Patients with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 at screening
• Patients with severe hepatic impairment of Child-Turcotte-Pugh class C at screening
• Patients treated with antidiabetic drugs thiazolidinediones (TZD) (rosiglitazone and pioglitazone) prior to screening
• Patients who were receiving SGLT2 inhibitors (e.g., dapagliflozin, canagliflozin, or empagliflozin) within 3 months prior to screening
• Known allergy or hypersensitivity to any component of the study drugs
• Current or previous participation in another clinical study involving the systemic or ocular administration of an investigational drug or device within 6 months of screening

• Macular edema caused by other conditions than diabetic macular edema or coexisting with DME such as retinal vein occlusion, choroidal neovascularization (CNV), or uveitic cystoid macular edema
• History of postoperative cystoid macular edema (Irvine-Gass syndrome)
• Cataract extraction within 3 months prior to screening
• Patients who had previous macular laser treatment
• Patients who had peripheral panretinal photocoagulation laser (PRP) treatment within 6 months prior to screening
• Patients who have been treated with intravitreal anti-VEGF or intravitreal corticosteroids within 6 months prior to screening
• The use of corticosteroids or non-steroidal anti-inflammatory eye drops within 1 month prior to screening
• Patients on topical prostaglandin analogs (e.g., latanoprost, travoprost, ioprost, or tafluprost) at screening
• History of vitrectomy or scleral buckling
• Presence of diffuse vitreomacular traction or thick epiretinal membrane on OCT causing significant traction
• Presence of tractional retinal detachment involving the macula and requiring vitrectomy
• Presence of other associated macular pathology (e.g., macular scars or macular holes) on OCT
• Presence of rubeosis iridis
• Signs of hypertensive retinopathy (arterioral spasm or silver wiring of blood vessels)
• Presence of glaucoma
• Aphakia
• Yttrium aluminum garnet (YAG) laser capsulotomy within 3 months prior to screening
• Patients diagnosed with ocular surface infections until treated prior to receiving the intravitreal injections

• The non-study eye receiving simultaneous intravitreal anti-VEGF treatment with the study eye

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alexandria University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Amira A. Nayel, MSc

Role: PRINCIPAL_INVESTIGATOR

Clinical researcher and PhD student at the Faculty of Pharmacy, Alexandria University

Locations

Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University

Alexandria, Alexandria Governorate, Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

Amira A. Nayel, Pharm.D, MSc

Role: CONTACT

gs-amira.nayel@alexu.edu.eg

+201022715779

Facility Contacts

Hesham Elgoweini, PhD

Role: primary

ethics.comm@alexmed.edu.eg

+201287740750

Other Identifiers

0202071

Identifier Type: -

Identifier Source: org_study_id